Sitagliptin is a type 2 diabetes medication that works by inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down glucagon-like peptide-1 (GLP-1) hormone. Watch this video to learn more about sitagliptin and its mechanism of action.
For other pharmacology content, do check out: pharmaedinsights.wordpress.com/
Disclaimer: This RU-vid video is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. Information on this video should not be considered as a substitute for advice from a healthcare professional. The statements made about specific products are not to diagnose, treat, cure, or prevent disease.
References:
1. Ahrén B. DPP-4 Inhibition and the Path to Clinical Proof. Front Endocrinol (Lausanne). 2019;10:376. Published 2019 Jun 19. doi:10.3389/fendo.2019.00376
2. Scott LJ. Sitagliptin: A Review in Type 2 Diabetes. Drugs. 2017;77(2):209-224. doi:10.1007/s40265-016-0686-9
#sitagliptin #diabetes #pharmacology #type2diabetes #antidiabetic #GLP-1 #DPP4inhibitor #insulin #glucagon #bloodsugarcontrol
31 окт 2023
